New Korean Accounting Guidelines Aim For More Flexible Biopharma Practices
New Treatment Of R&D Costs
Executive Summary
South Korea moves to lay out clearer accounting guidelines related to R&D costs for pharma and biotech companies, making improvements to earlier official guidance in 2018 in order to ease uncertainties and help foster the sector.